Up-regulation of Urokinase-type Plasminogen Activator in Squamous Cell Carcinoma of Human Larynx

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Oct 1

PMID 8883400

Citations 1

Authors

S Parolini

D Flagiello

A Cinquetti

R Gozzi

S Cristini

J Cappiello

P Nicolai

M Rusnati

M Presta

M M Tosatti

Affiliations

Soon will be listed here.

Abstract

The expression of urokinase-type plasminogen activator (uPA) was investigated in squamous cell carcinoma of the human larynx. For this purpose, tissue extracts from 25 matched samples of normal mucosa and neoplastic larynx were compared for the levels of uPA activity as evaluated by a chromogenic PA assay and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. Also, uPA antigen was quantified by enzyme-linked immunosorbent assay (ELISA) in 19 cases. The results demonstrate a significant increase in the levels of uPA activity and protein in tumour tissue extracts, more pronounced in tumours with lymph node metastases. Immunohistochemistry performed on 70 biopsies showed that uPA positivity is present both in neoplastic cells and in fibroblast-like cells and macrophages. However, depending on the histological grading and invasive capacity of the tumour, a pronounced intra- and intertumoral heterogeneity in uPA staining was observed. In situ hybridisation confirmed the presence of uPA mRNA in both tumour and stromal cells. The present study provides experimental evidence for a role of uPA in the invasive growth of human laryngeal carcinoma.

Citing Articles

Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W Mol Cell Proteomics. 2012; 11(11):1404-15.

PMID: 22918226 PMC: 3494179. DOI: 10.1074/mcp.M112.020933.

References

Wilson E, Becker M, Hoal E, DOWDLE E . Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res. 1980; 40(3):933-8. View

Markus G, Takita H, Camiolo S, Corasanti J, Evers J, Hobika G . Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res. 1980; 40(3):841-8. View

Camiolo S, Markus G, Evers J, Hobika G, DePasquale J, Beckley S . Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity. Int J Cancer. 1981; 27(2):191-8. DOI: 10.1002/ijc.2910270211. View

Camiolo S, Markus G, ENGLANDER L, Siuta M, Hobika G, Kohga S . Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res. 1984; 44(1):311-8. View

OSSOWSKI L, Reich E . Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983; 35(3 Pt 2):611-9. DOI: 10.1016/0092-8674(83)90093-4. View

Colombi M, Barlati S, Magdelenat H . Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes. Cancer Res. 1984; 44(7):2971-5. View

Skriver L, Larsson L, Kielberg V, Nielsen L, Andresen P, Kristensen P . Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol. 1984; 99(2):753-7. PMC: 2113289. DOI: 10.1083/jcb.99.2.753. View

Kohga S, Harvey S, WEAVER R, Markus G . Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res. 1985; 45(4):1787-96. View

Whitney C, Satyaswaroop P, Mortel R . Plasminogen activator activity in human endometrial carcinoma. Gynecol Oncol. 1985; 22(1):97-104. DOI: 10.1016/0090-8258(85)90012-5. View

10.

Dano K, Andreasen P, Kristensen P, Nielsen L, Skriver L . Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985; 44:139-266. DOI: 10.1016/s0065-230x(08)60028-7. View

11.

Mignatti P, Robbins E, Rifkin D . Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986; 47(4):487-98. DOI: 10.1016/0092-8674(86)90613-6. View

12.

Vassalli J, Belin D . Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987; 214(1):187-91. DOI: 10.1016/0014-5793(87)80039-x. View

13.

Sappino A, Busso N, Belin D, Vassalli J . Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res. 1987; 47(15):4043-6. View

14.

de Bruin P, Griffioen G, Verspaget H, Verheijen J, Lamers C . Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res. 1987; 47(17):4654-7. View

15.

Hearing V, Law L, Corti A, Appella E, Blasi F . Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 1988; 48(5):1270-8. View

16.

Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A . The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res. 1988; 50(4):527-35. DOI: 10.1016/0049-3848(88)90201-0. View

17.

Sim P, Stephens R, Fayle D, Doe W . Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int J Cancer. 1988; 42(4):483-8. DOI: 10.1002/ijc.2910420402. View

18.

Saksela O, Rifkin D . Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 1988; 4:93-126. DOI: 10.1146/annurev.cb.04.110188.000521. View

19.

OSSOWSKI L . In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol. 1988; 107(6 Pt 1):2437-45. PMC: 2115626. DOI: 10.1083/jcb.107.6.2437. View

20.

Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S, Ishikawa E . Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res. 1989; 49(4):1067-70. View